Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus concurrent chemoradiotherapy in locally advanced head and neck squamous cell carcinoma
ChiCTR2100046011Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Guangxi University of Science and Technology
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of sintilimab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by The Second Affiliated Hospital of Guangxi University of Science and Technology. Primary endpoints: Objective response rate, Progression-free survival and 2 more. Started Jul 2021; status: recruiting.
02
Drugs
sintilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2100046011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046011.